Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Q3 and nine-month 2026 financial results through September 30, 2026.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Q3 and nine-month 2026 financial results through September 30, 2026
- Includes Corvus Pharmaceuticals’ September 30, 2026 financial position
- Business update may affect investor assessment of pipeline progress and funding needs
- Exhibit 99.1 contains the detailed results and company update
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $20.3M, or $0.22 per share, versus $10.2M, or $0.12, in Q3 2025
- R&D expense $17.8M versus $8.5M, reflecting accelerated soquelitinib clinical development
- Cash, equivalents and marketable securities $202.9M, including $189.4M financing proceeds, funding operations into Q2 2028
- Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track, preserving key registrational catalysts
- 2027 catalysts include Angel Pharma atopic dermatitis data in March, hidradenitis suppurativa data in 1H, and asthma Phase 2 initiation by Q1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.